Compare
NextCure, Inc. vs Opus Genetics, Inc. vs Coya Therapeutics, Inc. vs Unicycive Therapeutics, Inc.
| Latest fiscal year | NextCure, Inc. NXTC | Opus Genetics, Inc. IRD | Coya Therapeutics, Inc. COYA | Unicycive Therapeutics, Inc. UNCY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $14.20M | $7.95M | n/a |
| Revenue growth (YoY) | n/a | +29.1% | +123.6% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -271.9% | -283.9% | n/a |
| Net margin | n/a | -349.3% | -267.1% | n/a |
| Net income | -$55.84M | -$49.59M | -$21.23M | -$26.55M |
| EPS (Diluted) | -$19.65 | -$0.80 | -$1.27 | -$1.67 |
| Operating cash flow | -$49.61M | -$35.25M | -$10.74M | -$31.32M |
| Free cash flow | n/a | n/a | n/a | -$31.34M |
| Cash & equivalents | $25.98M | $45.09M | $46.82M | $29.20M |
| Total assets | $50.18M | $50.24M | $49.95M | $49.13M |
| Total liabilities | $15.24M | $34.90M | $6.92M | $18.94M |
| Shareholders' equity | $34.94M | $15.35M | $43.03M | $30.20M |
| Return on year-end equity | -159.8% | -323.1% | -49.3% | -87.9% |
| Shares outstanding | 3.51M | 69.89M | 20.93M | 22.11M |
Revenue, most recent five fiscal years
| Fiscal year | NextCure, Inc. | Opus Genetics, Inc. | Coya Therapeutics, Inc. | Unicycive Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $22.38M Ended 2020-12-31 | $14.20M Ended 2025-12-31 | $7.95M Ended 2025-12-31 | $675.0K Ended 2023-12-31 |
| 1 year earlier | $6.35M Ended 2019-12-31 | $10.99M Ended 2024-12-31 | $3.55M Ended 2024-12-31 | $951.0K Ended 2022-12-31 |
| 2 years earlier | n/a | $19.05M Ended 2023-12-31 | $6.00M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $39.85M Ended 2022-12-31 | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $589.0K Ended 2021-12-31 | n/a | n/a |